Prescription drug · ANDA
Carbidopa and Levodopa NDC 50268-202
Carbidopa 25 mg/1; Levodopa 100 mg/1 · Tablet · Oral · AvPAK
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 50268-202-15 | 50268020215 | 50 BLISTER PACK in 1 BOX (50268-202-15) / 1 TABLET in 1 BLISTER PACK (50268-202-11)Marketed from Jun 23, 2026 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Carbidopa and Levodopa
- Generic name (nonproprietary)
- carbidopa and levodopa
- Active ingredients
- Carbidopa — 25 mg/1Levodopa — 100 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- AvPAK
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 073589
- Marketing start
- Listing expires
- Other FDA classes
- Aromatic (Chemical structure)
- Identifiers
- Product ID 50268-202_54f30b53-6bd0-225e-e063-6294a90af421SPL ID 54f30b53-6bd0-225e-e063-6294a90af421SPL set ID 54f30abc-97fa-00f0-e063-6394a90a155dRxCUI 197444UNII MNX7R8C5VO, 46627O600J
- Pharmacologic class
- Aromatic Amino Acid
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N450268020215followed by a unit qualifier and the quantityPackage 50268-0202-15. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE Carbidopa and levodopa tablets, USP are indicated in the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. Carbidopa allows patients treated for Parkinson's disease to use much lower doses of levodopa. Some patients who responded poorly to levodopa have improved on carbidopa and levodopa tablets. This is most likely due to decreased peripheral decarboxylation of levodopa caused by administration of carbidopa rather than by a primary effect of carbidopa on the nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa. Carbi…
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 073589
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Carbidopa and Levodopa | Carbidopa hydrate 25 mg/1; Levodopa 100 mg/1 | TabletOral | Cardinal Health 107, LLC | 55154-2643 |
| Carbidopa and Levodopa | Carbidopa 25 mg/1; Levodopa 100 mg/1 | TabletOral | NCS HealthCare of KY, LLC dba Vangard Labs | 0615-8536 |
| Carbidopa and Levodopa | Carbidopa hydrate 25 mg/1; Levodopa 100 mg/1 | TabletOral | Major Pharmaceuticals | 0904-7501 |
| Carbidopa and Levodopa | Carbidopa 25 mg/1; Levodopa 100 mg/1 | TabletOral | Dr. Reddy's Laboratories Inc | 75907-020 |